Cargando…
Corrigendum: Targeting Bcl-2 Proteins in Acute Myeloid Leukemia
Autores principales: | Wei, Yunxiong, Cao, Yaqing, Sun, Rui, Cheng, Lin, Xiong, Xia, Jin, Xin, He, Xiaoyuan, Lu, Wenyi, Zhao, Mingfeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7774455/ https://www.ncbi.nlm.nih.gov/pubmed/33392100 http://dx.doi.org/10.3389/fonc.2020.632775 |
Ejemplares similares
-
Targeting Bcl-2 Proteins in Acute Myeloid Leukemia
por: Wei, Yunxiong, et al.
Publicado: (2020) -
Low‐dose decitabine plus venetoclax is safe and effective as post‐transplant maintenance therapy for high‐risk acute myeloid leukemia and myelodysplastic syndrome
por: Wei, Yunxiong, et al.
Publicado: (2021) -
Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma
por: Cao, Yaqing, et al.
Publicado: (2019) -
Infection Temperature Affects the Phenotype and Function of Chimeric Antigen Receptor T Cells Produced via Lentiviral Technology
por: Jin, Xin, et al.
Publicado: (2021) -
Corrigendum: Murine models of acute myeloid leukemia
por: Kurtz, Kristen J., et al.
Publicado: (2023)